Aconitum Napellus Whole Atropa Belladonna Bryonia
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Aconitum Napellus Whole Atropa Belladonna Bryonia
- Multi-Component Botanical/Homeopathic Combination: Drug Identity Unresolved — Repurposing Evaluation Not Possible
Multi-Component Botanical/Homeopathic Combination: Drug Identity Unresolved — Repurposing Evaluation Not Possible
One-Sentence Summary
This candidate consists of twelve botanical and homeopathic components (including Atropa belladonna, nitroglycerin, Tanacetum parthenium, and Strychnos nux-vomica), without a unified INN or DrugBank ID. The TxGNN model returned no predicted new indications for this candidate, and the drug is not currently marketed in Taiwan. Without drug identity resolution, mechanism data, or model output, a formal repurposing evaluation cannot be completed at this time.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | None on record |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only) — no output available |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why This Evaluation Cannot Proceed
This candidate is a twelve-component mixture of botanical and homeopathic substances, including:
- Neurotoxic alkaloid sources: Aconitum napellus, Atropa belladonna, Gelsemium sempervirens, Strychnos nux-vomica, Spigelia anthelmia
- Fungal/ergot material: Claviceps purpurea sclerotium (the source of ergotamine)
- Conventional small-molecule drug: Nitroglycerin
- Herbal/phytomedicine components: Bryonia alba, Melilotus officinalis, Milk thistle (Silybum marianum), Tanacetum parthenium (feverfew), Sepia officinalis
Because this is a multi-component mixture without a unified DrugBank ID, TxGNN’s disease–gene–drug knowledge graph cannot resolve it to a single drug node. This explains why predicted_indications is empty. There is no single mechanism of action on record.
The presence of nitroglycerin (a vasodilator used in angina) alongside feverfew (historically used for migraine prophylaxis) suggests this may be a homeopathic or naturopathic proprietary formula, possibly targeting cardiovascular or headache indications — but this inference is speculative and unsupported by the data provided.
Currently, detailed mechanism of action data is not available. Based on known information, this combination lacks a unified pharmacological class, and no original approved indication could be confirmed from any regulatory source queried.
Safety Considerations
Please refer to the package insert for safety information.
Note for reviewers: Several components in this mixture carry significant inherent toxicity concerns even at low doses (e.g., Atropa belladonna contains atropine and scopolamine; Strychnos nux-vomica contains strychnine; Aconitum napellus contains aconitine). Any future clinical use assessment must include dedicated toxicological review of the full formulation.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN model returned no repurposing predictions for this candidate, likely because the multi-component mixture cannot be resolved to a single drug node in the knowledge graph. Without a unified drug identity, mechanism of action, safety profile, or regulatory history, no repurposing evaluation is possible at this stage.
To proceed, the following is needed:
- Drug identity resolution — Confirm whether this mixture is a registered proprietary product (e.g., a homeopathic OTC product). If so, retrieve its brand name, manufacturer, and primary indication.
- DrugBank ID assignment — Map each active component to its individual DrugBank entry, or identify if the combination has a composite entry.
- Mechanism of action data — Characterize the pharmacological action of each component individually, then assess additive or synergistic effects.
- Regulatory verification — Search TFDA, EMA, and US FDA homeopathic/OTC databases using the brand name (if known) rather than INN strings.
- TxGNN re-query by component — Run TxGNN separately for key single-ingredient components (e.g., nitroglycerin, Tanacetum parthenium) to generate component-level repurposing hypotheses.
- Safety data collection — Obtain the full product monograph or package insert to document known toxicity, contraindications, and drug interactions for the mixture.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.